JP2012528191A5 - - Google Patents

Download PDF

Info

Publication number
JP2012528191A5
JP2012528191A5 JP2012513262A JP2012513262A JP2012528191A5 JP 2012528191 A5 JP2012528191 A5 JP 2012528191A5 JP 2012513262 A JP2012513262 A JP 2012513262A JP 2012513262 A JP2012513262 A JP 2012513262A JP 2012528191 A5 JP2012528191 A5 JP 2012528191A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
peptide
muc1
weeks
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012513262A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012528191A (ja
JP5702371B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/036436 external-priority patent/WO2010138740A1/en
Publication of JP2012528191A publication Critical patent/JP2012528191A/ja
Publication of JP2012528191A5 publication Critical patent/JP2012528191A5/ja
Application granted granted Critical
Publication of JP5702371B2 publication Critical patent/JP5702371B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2012513262A 2009-05-27 2010-05-27 Ｍｕｃ１のアンタゴニストを使用した、炎症の阻害 Expired - Fee Related JP5702371B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18153009P 2009-05-27 2009-05-27
US61/181,530 2009-05-27
US25373009P 2009-10-21 2009-10-21
US61/253,730 2009-10-21
US30399710P 2010-02-12 2010-02-12
US61/303,997 2010-02-12
PCT/US2010/036436 WO2010138740A1 (en) 2009-05-27 2010-05-27 Inhibition 0f inflammation using antagonists of muc1

Publications (3)

Publication Number Publication Date
JP2012528191A JP2012528191A (ja) 2012-11-12
JP2012528191A5 true JP2012528191A5 (enExample) 2013-01-10
JP5702371B2 JP5702371B2 (ja) 2015-04-15

Family

ID=43223089

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012513262A Expired - Fee Related JP5702371B2 (ja) 2009-05-27 2010-05-27 Ｍｕｃ１のアンタゴニストを使用した、炎症の阻害

Country Status (9)

Country Link
US (2) US8614186B2 (enExample)
EP (1) EP2435062A4 (enExample)
JP (1) JP5702371B2 (enExample)
CN (1) CN102665748A (enExample)
AU (1) AU2010253834B2 (enExample)
CA (1) CA2763327C (enExample)
IL (1) IL216612A0 (enExample)
MX (1) MX2011012625A (enExample)
WO (1) WO2010138740A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011004082A (es) 2008-10-17 2011-10-14 Dana Farber Cancer Inst Inc Peptidos de dominio citoplasmico muc-1 como inhibidores del cancer.
WO2011100688A1 (en) * 2010-02-12 2011-08-18 Dana-Farber Cancer Institute, Inc. Improved antagonists of muc1
US20130101664A1 (en) 2011-08-18 2013-04-25 Donald W. Kufe Muc1 ligand traps for use in treating cancers
US9044421B2 (en) 2012-03-28 2015-06-02 Genus Oncology, Llc Treating MUC1-expressing cancers with combination therapies
US20150087598A1 (en) * 2012-05-11 2015-03-26 Dana-Farber Cancer Institute, Inc. Treating muc1-expressing cancers with helicase inhibitors
CN103848890B (zh) * 2012-11-30 2015-09-09 北京市结核病胸部肿瘤研究所 Muc1自身抗体识别的抗原多肽
US9572855B2 (en) 2013-03-11 2017-02-21 Dana-Farber Cancer Institute, Inc. Combination anti-estrogen receptor cancer therapy using MUC1 peptides and chemotherapeutics
US10507227B2 (en) 2014-04-15 2019-12-17 The Hospital For Sick Children Cationic antimicrobial peptides
JP6994939B2 (ja) * 2014-07-02 2022-02-04 インフレクティス・バイオサイエンス プロテオパチーの処置のためのベンジリデングアニジン誘導体の新規な治療的使用
EP3197474B1 (en) 2014-09-26 2023-06-07 Rajendra Sahai Bhatnagar Inhibitors of nf kappa-b activity for treatment of diseases and disorders
JP7366007B2 (ja) * 2017-09-13 2023-10-20 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング プロアドレノメジュリンに基づく輸液療法のガイダンスのための方法
CN107952069A (zh) * 2017-11-24 2018-04-24 长春百克生物科技股份公司 重组疫苗及其应用
CN114555624A (zh) * 2019-06-06 2022-05-27 悉尼大学 抗炎剂
CN117929754B (zh) * 2024-01-25 2025-02-11 广州医科大学附属第一医院（广州呼吸中心） Muc1-c段在肺动脉高压预防或治疗药物制备中的应用
WO2025217515A2 (en) * 2024-04-12 2025-10-16 Dana-Farber Cancer Institute, Inc. Identification of muc1-c as a target for the treatment of squamous cell carcinomas
WO2025231266A1 (en) * 2024-05-01 2025-11-06 Emory University Use of muc1 mimetic peptide inhibitors for inhibition of mucus secretion
CN119236051B (zh) * 2024-09-29 2025-12-19 北京大学 Muc1抑制剂在制备预防、治疗细菌感染药物中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5912232A (en) * 1994-09-23 1999-06-15 Board Of Regents Of The University Of Nebraska Anti-inflammatory polypeptide antagonists of human I1-8
US6548643B1 (en) * 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
NO961031D0 (no) 1996-03-13 1996-03-13 Det Norske Radiumshospital Tum Fremgangsmåte til å drepe uönskede målceller
US20020044943A1 (en) * 1997-09-10 2002-04-18 Longenecker B. Michael MUC-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions
CA2354644A1 (en) * 1998-12-11 2000-06-15 Biomira, Inc. Muc-1 antagonists and methods of treating immune disorders
WO2001018035A2 (en) * 1999-09-08 2001-03-15 Transgene S.A. Muc-1 derived peptides
WO2001057068A1 (en) 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy
WO2002022685A2 (en) 2000-09-11 2002-03-21 Kufe Donald W Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
ATE552859T1 (de) * 2000-09-13 2012-04-15 Praecis Pharm Inc Pharmazeutische formulierungen zur kontinuierlichen abgabe von peptiden
WO2002058450A2 (en) 2000-12-22 2002-08-01 Dana-Faber Cancer Institute, Inc. Regulation of cell growth by muc1
AU2002303390A1 (en) 2001-04-18 2002-11-05 Dana-Farber Cancer Institute, Inc. Induction of apoptosis by cellular stress
US7247297B2 (en) 2001-09-14 2007-07-24 The University Of Chicago Use of DF3/MUC1 regulated expression in gene therapy
CA2842429A1 (en) * 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
EP1538164A1 (en) * 2003-12-04 2005-06-08 Vectron Therapeutics AG RGD targeting moiety its production and use
JP2007523092A (ja) 2004-02-17 2007-08-16 キャンサーバックス コーポレイション 新脈管形成阻害のための方法および組成物
EP1718367A1 (en) 2004-02-23 2006-11-08 Genzyme Corporation Muc1 antagonist enhancement of death receptor ligand-induced apoptosis
WO2005101021A1 (en) 2004-04-13 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled adrenergic alpha-1d-receptor (adra1d)
US20070207209A1 (en) 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
JP2008537095A (ja) * 2005-02-15 2008-09-11 ダナ−ファーバー キャンサー インスティテュート インク． Ｍｕｃ１活性の調節
JP5116663B2 (ja) * 2005-04-15 2013-01-09 アリゾナ バイオメディカル リサーチ コミッション 転移癌の処置のための治療用ペプチド
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1946113A4 (en) 2005-08-22 2010-03-10 Dana Farber Cancer Inst Inc MITOCHONDRIAL LOCALIZATION OF MUC1
GB0519303D0 (en) 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
WO2008097844A2 (en) 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
WO2008101121A2 (en) 2007-02-14 2008-08-21 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by muc1 and klf proteins
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
MX2011004082A (es) * 2008-10-17 2011-10-14 Dana Farber Cancer Inst Inc Peptidos de dominio citoplasmico muc-1 como inhibidores del cancer.
WO2011100688A1 (en) * 2010-02-12 2011-08-18 Dana-Farber Cancer Institute, Inc. Improved antagonists of muc1
WO2011115819A2 (en) * 2010-03-15 2011-09-22 Genus Oncology, Llc Small molecule inhibitors of muc1 and methods of identifying the same

Similar Documents

Publication Publication Date Title
JP7818648B2 (ja) Ｇｐｃｒヘテロマー阻害剤及びその用途
CA3042358C (en) Zinc fingers and related adenovirus-associated virus vectors for the treatment of polyglutamine diseases, such as Huntington's disease
US11246907B2 (en) Immunosuppressive agents and their use in therapy
EP2443137B1 (en) Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer
JP6352911B2 (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
US8211852B2 (en) Molecules and methods of using same for treating CCR5/CCR5 ligands associated diseases
JP2020501550A5 (enExample)
AU2020268619A1 (en) Treatment and prevention of metabolic diseases
JP2009509535A5 (enExample)
WO2011038149A2 (en) Methods of treating inflammation
JP2012508698A5 (enExample)
JP2019527192A (ja) 全身性エリテマトーデスの診断及び治療方法
Segal et al. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis
JP4313433B2 (ja) イミュノグロブリン結合能を有するペプチド
US11560417B2 (en) Isolated polypeptides of CD44 and uses thereof
JP4705694B2 (ja) イミュノグロブリン結合能を有するペプチド
WO2015098113A1 (ja) 悪性腫瘍の治療薬
WO2015134610A1 (en) Methods for treating diabetic nephropathy
JP4751407B2 (ja) ヒトｔ細胞白血病ウイルス感染あるいは成人ｔ細胞白血病発症の検出法、その診断薬、ならびにその予防および治療の為の薬剤
KR20160086864A (ko) 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
CN108660203A (zh) Cxcr2基因在心脏相关疾病中的用途
CA3092091A1 (en) Methods of treating nash and compositions therefore
JP2011213704A (ja) Ｅｂｎａ１機能阻害剤
JP2019064968A (ja) 血管新生制御剤及びその利用方法
Wang et al. Emerging Mechanisms and Therapeutic Strategies in Dilated Cardiomyopathy